ELI LILLY & Co
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Over 600,000 seniors enrolled in Medicare's GLP-1 Bridge program in two months, saving $216 million. Eli Lilly (LLY) and Novo Nordisk (NVO) supply drugs at $245/month. Jefferies estimates $1.5B-$1.8B annualized revenue for the program. KFF estimates 3.8M eligible beneficiaries. Enrollment may reach 25% soon, but adherence is uncertain.
Upper Macungie Township approved Eli Lilly's final land development plan for a $3.5 billion pharmaceutical plant. The 797,432-square-foot facility will create 2,000 construction jobs and involve final assembly of injectable medicines. The project will be completed in phases, with the first phase including an amenities building and visitor center.
Eli Lilly (LLY) aims for Mounjaro to reach $124M in African sales by June 2027, per distributor Aspen Pharmacare. South Africa's GLP-1 market grew to 2.8B rand, with Mounjaro's share rising to 53%. Lilly's global Mounjaro sales were $9.94B last quarter. LLY stock is 24.44% below its GF Value estimate of $1,530.
Over the past 7 days, alphai's AI scored 79 news stories mentioning LLY (ELI LILLY & Co). Coverage has skewed bullish: 62 bullish, 11 neutral, and 6 bearish.
Recent LLY coverage spans financial news, regulation and sector analysis.
In the last 30 days, LLY insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($16.0M). The most active reporter was Zakrowski Donald A, SVP, Finance, & CAO, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Potential revenue boost from government program.
The approval enables construction of a large manufacturing campus, creating ~2,000 construction jobs and expanding Lilly's production capacity.
New regional sales target adds modest upside potential but unlikely to move the stock materially.
New product may capture share from existing GLP‑1 injectables.
Label expansion may protect Lilly's diabetes sales and support pricing, narrowing insurer coverage cuts.
alphai scores every news story that mentions LLY with an AI model for sentiment and relevance, and aggregates insider trades from ELI LILLY & Co's SEC EDGAR Form 4 filings. Figures refresh continuously.
Over 600,000 seniors enrolled in Medicare's GLP-1 Bridge program in two months, saving $216 million. Eli Lilly (LLY) and Novo Nordisk (NVO) supply drugs at $245/month. Jefferies estimates $1.5B-$1.8B annualized revenue for the program. KFF estimates 3.8M eligible beneficiaries. Enrollment may reach 25% soon, but adherence is uncertain.
2 min readUpper Macungie Township approved Eli Lilly's final land development plan for a $3.5 billion pharmaceutical plant. The 797,432-square-foot facility will create 2,000 construction jobs and involve final assembly of injectable medicines. The project will be completed in phases, with the first phase including an amenities building and visitor center.
2 min readEli Lilly (LLY) aims for Mounjaro to reach $124M in African sales by June 2027, per distributor Aspen Pharmacare. South Africa's GLP-1 market grew to 2.8B rand, with Mounjaro's share rising to 53%. Lilly's global Mounjaro sales were $9.94B last quarter. LLY stock is 24.44% below its GF Value estimate of $1,530.
1 min readOzempic is the most well-known GLP-1 medication, but data shows it accounts for only 7.1% of use. Tirzepatide-based drugs like Zepbound lead in prescriptions. Insurance coverage and cost influence prescribing decisions. Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) have different FDA approvals and efficacy profiles. First-time semaglutide prescriptions fell 13.3% from March to June 2026.
3 min readEli Lilly's Mounjaro Q2 revenue surged 91% to $9.94 billion, with full-year guidance raised to $85B-$87B. The FDA expanded Mounjaro's label to include cardiovascular benefits, which may help defend diabetes reimbursement as employer coverage for GLP-1 drugs drops. Shares trade at $1,174.61, down 6.44% in the past week.
2 min readEli Lilly's GLP-1 weight-loss pill, Foundayo, is now available in UK pharmacies via private prescription, following MHRA approval. The tablet offers convenience over injectables and has shown significant weight loss in trials. Eli Lilly is working with NICE for potential NHS inclusion. Counterfeit risks are a concern, with 97% of pharmacies worried about unlicensed products. The company is exploring tech solutions for supply chain security.
2 min readEli Lilly (LLY) reported Q2 2026 revenue of $22.974B, up 48% YoY, with Mounjaro contributing $9.943B. EPS guidance raised to $35.50-$36.50. Shares at $1,156.73, up 8.16% YTD. Analysts see modest upside to $1,315.04, but a model suggests $1,398.96 base case. Potential catalysts include FDA approvals and pipeline developments.
3 min readJPMorgan reiterated an Overweight rating and $1,400 price target for Eli Lilly (NYSE:LLY), citing growth in its incretin business. The stock has risen 59% in the past year, trading at $1,171 with a $1.05 trillion market cap. JPMorgan expects Mounjaro and Zepbound to drive future growth. Eli Lilly recently acquired Merida Biosciences for $2.875 billion and launched Foundayo in the UK.
2 min readFDA approved a phase 1 trial for Protagenic Therapeutics' PT00114 for generalized anxiety disorder. Takeda's Oveporexton (Orzeyful) was approved for narcolepsy type 1. Roche and Eli Lilly's Elecsys Phospho-Tau (217P) Plasma test and C2N Diagnostics' PrecivityAD2 for Alzheimer's disease also received FDA clearance.
2 min readAnalysts reiterated Buy ratings on Immunic (IMUX) with a $29 target, Incyte (INCY) with a $150 target, and Eli Lilly (LLY) with a $1600 target. Consensus targets suggest 167.5%, 6.6%, and 19.1% upside respectively.
2 min read
